Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized study to evaluate the safety, tolerability, and efficacy
of 200 mg CAMB and 400 mg CAMB compared with a single 150 mg dose of fluconazole in the
treatment of moderate to severe VVC.
Phase:
Phase 2
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Treatments:
Amphotericin B Fluconazole Liposomal amphotericin B